

**Amendments to the Specification**

On Page 1 of the specification, please replace the first paragraph with the following amended paragraph:


**RELATED APPLICATIONS**

This application is the National Stage of International Application No. PCT/US2004/043474, filed December 22, 2004, which ~~The present invention~~ claims priority to U.S. Provisional Application Serial No. 60/533,024, filed 12/29/2003, which is incorporated herein by reference.


On Page 41 of the specification, please replace the last line with the following amended line:

independently chloro, bromo, or iodo;  $R_{3a}$  is  $-Z-R_{4b}$ ,  $-Z-X''_a-R_4$ ,  $-Z-X''_b-Y'-R_4$ , or ~~and~~


On Page 49 of the specification, please replace




in Reaction Scheme IV with:




On Page 49 of the specification, please replace




in Reaction Scheme IV with :



On Page 49 of the specification, please replace



in Reaction Scheme IV with:



On Page 55 of the specification, please replace the last paragraph with the following amended paragraph:

The reduction described in Reaction Scheme IX can also be used to prepare a tetrahydro-1H-imidazo[4,5-c][1,5]naphthyridin-6-amine~~tetrahydro-1H-imidazo[4,5-c]quinolin-6-amine~~ of Formula LXVII, as shown in Reaction Scheme X, wherein X, X', Y, n, R<sub>a</sub>, and R<sub>1a</sub> are as defined above. The product of Formula LXVII, a subgenus of Formulas I and II, or a pharmaceutically acceptable salt thereof can be isolated by conventional methods.